drugset / Trial / NCT04526717
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
NaSingle-groupOpen-labelTreatment
Summary
Indication : Treatment of Subject with COVID-19 infection Phase : Phase I Duration of Study : 12 day Sample size : at least 15 subjects Methodology : Classical 3+3 design Investigational Product : MPT0B640, 15, 30, 60, 80 and 100mg, oral suspension Study Objective 1. Primary Objective To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640 2. Secondary Objectives To evaluate the safety and tolerability of MPT0B640 during entire study period To assess the efficacy of MPT0B640 To characterize the 48 hours PK of MPT0B640
Timeline
- Start
- 2021-12
- Primary completion
- 2022-12
- Completion
- 2022-12
Outcome
Outcome not reported
Stopped: “Study was determined not to initiate.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MPT0B640 | Unknown | 15 mg | Oral |
| Subject | MPT0B640 | Unknown | 30 mg | Oral |
| Subject | MPT0B640 | Unknown | 60 mg | Oral |
| Subject | MPT0B640 | Unknown | 80 mg | Oral |
| Subject | MPT0B640 | Unknown | 100 mg | Oral |